Extended Data Fig. 10: Clinical analysis of CLL and HCC.
From: The U1 spliceosomal RNA is recurrently mutated in multiple cancers
a, Kaplan–Meier plot of overall survival for CLL. P value is from the Cox model. b, Independent prognostic value of the U1 g.3A>C mutation in CLL. Multivariate Cox model results for time to first treatment in 301 patients with CLL (number of events = 153). HR, hazard ratio; CI, confidence interval. c, U1 mutation frequency by disease stage in CLL. A and B/C, Binet A and B/C stages. d, Kaplan–Meier plot of overall survival for HCC samples in the LIRI-JP project. MUT indicates samples with the g.3A>C mutation and WT indicates samples without the g.3A>C mutation; 13 MUT and 116 WT samples are used. e, f, Kaplan–Meier plots of OS (e) and progression-free interval (f) for HCC samples in the LIHC-US project. MUT indicates samples with the g.3A>C mutation and WT indicates samples without the g.3A>C mutation; 15 MUT and 335 WT samples are used. For d–f, P values are from two-sided log-rank tests; g, U1 mutation frequency by disease stage in HCC. For LIRI-JP, staging uses the Liver Cancer Study Group of Japan system. For LIHC-US, staging uses the American Joint Committee on Cancer system.
